AmberCell Solutions - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 4,101,275 | 4,607,245 | 7,794,881 | 8,806,873 | 9,195,041 | 14,244,984 | 17,949,614 | 21,861,224 |
| Profit before tax | 674,289 | 581,414 | 1,660,930 | 1,252,853 | 1,120,835 | 1,886,706 | 2,472,333 | 3,371,214 |
| Net profit | 575,436 | 511,165 | 1,422,910 | 1,069,101 | 959,222 | 1,579,851 | 2,083,013 | 2,782,604 |
| Equity | 2,006,072 | 2,524,740 | 1,989,550 | 1,481,152 | 1,440,375 | 1,772,237 | 2,874,983 | 5,657,587 |
| Liabilities | 972,840 | 863,744 | 1,090,813 | 2,543,372 | 3,141,500 | 4,717,084 | 4,628,410 | 4,132,269 |
| Non-current assets | 161,120 | 257,493 | 299,657 | 357,201 | 534,105 | 817,208 | 820,416 | 1,220,766 |
| Current assets | 2,849,645 | 3,125,078 | 2,776,862 | 3,664,430 | 4,068,273 | 5,682,027 | 6,689,230 | 8,479,145 |
| Total assets | 3,010,765 | 3,382,571 | 3,076,519 | 4,021,631 | 4,602,378 | 6,499,235 | 7,509,646 | 9,699,911 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 631,684 | 940,562 | 1,192,289 |
| Social insurance contributions | - | - | - | - | - | 239,755 | 307,641 | 397,086 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +30.5% | +12.3% | +69.2% | +13.0% | +4.4% | +54.9% | +26.0% | +21.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 19.1% | 15.1% | 46.3% | 26.6% | 20.8% | 24.3% | 27.7% | 28.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 28.7% | 20.2% | 71.5% | 72.2% | 66.6% | 89.1% | 72.5% | 49.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 14.0% | 11.1% | 18.3% | 12.1% | 10.4% | 11.1% | 11.6% | 12.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 16.4% | 12.6% | 21.3% | 14.2% | 12.2% | 13.2% | 13.8% | 15.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.5 | 0.3 | 0.5 | 1.7 | 2.2 | 2.7 | 1.6 | 0.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 447,410 | 412,588 | 850,348 | 1,273,277 | 1,103,409 | 700,574 | 735,137 | 699,559 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
AmberCell Solutions - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-01-17 | 2023-01-18 | 8669.21 |
AmberCell Solutions - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-02-28 | 2026-03-11 | 0.1 |
| 2026-02-21 | 2026-02-21 | 0.1 |
| 2026-01-14 | 2026-01-15 | 67.61 |
| 2026-01-13 | 2026-01-13 | 67.76 |
| 2025-05-01 | 2025-05-08 | 0.33 |
| 2025-04-30 | 2025-04-30 | 654.15 |
| 2025-04-28 | 2025-04-29 | 653.6 |
| 2025-04-23 | 2025-04-23 | 653.43 |
| 2025-04-20 | 2025-04-22 | 652.75 |
| 2025-04-19 | 2025-04-19 | 649.69 |
| 2025-04-18 | 2025-04-18 | 644.52 |
| 2024-11-20 | 2024-11-23 | 70.21 |
| 2024-11-18 | 2024-11-19 | 70.13 |
| 2024-10-12 | 2024-10-15 | 988.67 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
AmberCell Solutions, UAB (code 302591590) is a private limited liability company operating in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €21.86M, up 21.8% year on year and 53.5% over two years. Net profit reached €2.78M, compared with €2.08M in 2024 and €1.58M in 2023, showing a steady upward trajectory. Profitability remained solid, with a 12.7% profit margin in 2025 after 11.6% in 2024 and 11.1% in 2023. The balance sheet also strengthened: total assets increased to €9.70M in 2025 from €7.51M in 2024 and €6.50M in 2023, while equity rose to €5.66M. Liabilities declined to €4.13M from €4.63M a year earlier. Key ratios for 2025 indicate efficient use of capital and assets, with ROE at 49.2%, ROA at 28.7%, debt-to-equity at 0.73, and asset turnover at 2.25x. Revenue per employee was €705.2K, supporting a strong productivity profile.